Biogen/$BIIB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Ticker

$BIIB
Sector
Primary listing

Employees

7,605

Biogen Metrics

BasicAdvanced
$22B
14.56
$10.45
0.13
-

What the Analysts think about Biogen

Analyst ratings (Buy, Hold, Sell) for Biogen stock.

Bulls say / Bears say

Biogen beat Q1 2025 revenue estimates with 6% year-over-year growth to $2.43 billion, driven by strong demand for rare disease therapies Skyclarys and Spinraza (Reuters).
The European Commission authorized Leqembi for treating early-stage Alzheimer’s, making it the first EU-approved drug targeting amyloid beta and expanding Biogen’s market access in Europe (Reuters).
FDA approval of Leqembi IQLIK, an at-home injectable maintenance therapy, is expected to enhance patient accessibility and adoption by simplifying treatment relative to IV infusions (Reuters).
Declining sales of core multiple sclerosis medicines during Q1 2025 highlight intensifying competition and revenue pressure in Biogen’s legacy franchise (Reuters).
Biogen lowered its 2025 earnings guidance to $14.50–$15.50 per share, incorporating a $165 million charge from a licensing deal, signaling headwinds from pipeline investments (Reuters).
A U.S. judge ruled Biogen must pay Genentech over $88 million in royalties for Tysabri, introducing unexpected legal liabilities and financial risk (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Biogen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Biogen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIIB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs